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ABSTRACT
Objective The gut microbiota influences many aspects of 
human health. We investigated the magnitude and duration 
of changes in gut microbiota in response to antibiotics 
commonly prescribed in UK primary care.
Methods We searched MEDLINE, EMBASE and AMED, 
all years up to May 2020 including all study designs, 
collecting and analysing data on the effect of antibiotics 
prescribed for respiratory and urinary tract infections. We 
followed the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses and Cochrane standard 
methods. Risk of bias was evaluated using the Critical 
Appraisal Skills Programme. Narrative synthesis was used 
to report the themes emerging from the data.
Main outcome measures Primary outcomes were 
antibiotic- induced changes in the composition and/or 
diversity of the gut microbiota. Secondary outcome was 
the time for the microbiota to return to baseline.
Results Thirty- one articles with low or unclear risk of 
bias showed that antibiotics impact the gut microbiota by 
causing rapid and diminished levels of bacterial diversity 
and changes in relative abundances. After cessation of 
treatment, gut bacteria recover, in most individuals, to 
their baseline state within a few weeks. Some studies 
suggested longer term effects from 2 to 6 months. 
Considerable heterogeneity in methodology makes the 
studies prone to biases and other confounding factors. 
Doxycycline was associated with a marked short- term 
decrease in Bifidobacterium diversity. Clarithromycin 
decreased the populations of Enterobacteria, and the 
anaerobic bacteria Bifidobacterium sp and Lactobacillus 
sp in numbers and diversity for up to 5 weeks. 
Phenoxymethylpenicillin, nitrofurantoin and amoxicillin had 
very little effect on the gut microbiome.
Conclusions Despite substantial heterogeneity of the 
studies and small sample sizes, there is evidence that 
antibiotics commonly used in primary care influence the 
composition of the gastrointestinal microbiota. Larger 
population- based studies are needed to fully understand 
how antibiotics modulate the microbiota, and to determine 
if these are associated with (longer term) health 
consequences.
PROSPERO registration number CRD42017073750.
INTRODUCTION
In the UK, between 2000 and 2014, antibi-
otic prescriptions increased from 14.3 to 
19.7 defined daily doses (DDDs) per 1000 
inhabitants per day. The volume of antibiotic 
prescribing has since decreased, reaching 
18.7 DDDs per 1000 inhabitants per day in 
2016 (http://www. oecd. org/). Misuse and 
overuse of antimicrobials, not only in medical 
sectors, but also in veterinary and agricultural 
sectors, result in increasing resistance, which 
globally limits our ability to control infec-
tions. Decreasing antibiotic consumption 
is a key target to dealing with the problem, 
and the UK has implemented antimicrobial 
Strengths and limitations of this study
 ► This review addresses the antibiotic- induced 
changes in gut microbiota for the most commonly 
prescribed antibiotics in UK primary care for the 
infections most frequently seen in general practice: 
respiratory tract and urinary tract infections.
 ► The study used a complete and inclusive search 
strategy complemented by manually scanning ref-
erence lists of identified articles for further relevant 
publications.
 ► We searched three databases, all years up to May 
2020, for any study type, with clearly defined criteria 
for study inclusion.
 ► It was not feasible to combine results in a meta- 
analysis as the majority of the studies were small, 
poorly randomised and with limited follow- up. There 
was considerable heterogeneity in methodology, 
which makes them prone to biases and other con-
founding factors.
 ► This limits our understanding of the long- term 
changes induced by commonly prescribed antibi-
otics, the ability to modify antibiotic treatment to 
each situation and to make recommendations to 
clinicians.
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stewardship interventions in primary care1 and detailed 
a 5- year action plan for tackling antimicrobial resistance.2
Data analysed from The Health Improvement Network 
(THIN) database stated that a median prescribing rate 
among participating practices was 626 antibiotic prescrip-
tions/1000 patients (IQR 543–699), 69% of which could 
be linked to a body system and/or clinical condition.3 Of 
these prescriptions, 46% were linked to respiratory tract 
infections (RTIs) and 22.7% to infections of the urogen-
ital tract. About half of all antibiotics prescribed were 
penicillin, of which approximately 55% was amoxicillin; 
this is followed by 13% macrolide use and 12% tetracy-
cline.3 General practicioner (GP) consultation rates in 
England and Wales show that a quarter of the population 
will visit their GP because of an RTI each year.4 Antibiotic 
use to treat such infection varies between individual clini-
cians and countries,4–6 but accounts for 60% of all antibi-
otic prescribing in general practice.7–9 Similarly, urinary 
tract infections (UTIs) are commonly seen in primary 
care.10 Patients are frequently treated with antibiotics, 
even though the infection often is not microbiologically 
confirmed.11 The overuse of antibiotics for conditions 
that are not serious or where antibiotic treatment is not 
appropriate for the illness has led to their reduced effec-
tiveness and emergence of resistant bacteria.
The normal gut microbiota consists of approximately 
800–1000 different bacterial species and more than 7000 
different strains.12 ‘Normal’ is defined as the commensal 
species predominantly and consistently found in the 
gut of healthy human. The composition of the oesopha-
geal and gastric microbiomes is distinct from that of the 
colon. There is a greater diversity of species and number 
per gram of contents in the colon, reflecting its higher 
pH.13 14 The core microbiome in healthy individuals is 
dominated by phyla Firmicutes and Bacteroidetes (over 
90%), followed by Verrucomicrobia and Actinobacteria.13 
Some essential functions of a healthy gut microbiota 
include vitamin production, nutrient metabolism, immu-
nomodulation and protection against infection by inhib-
iting colonisation of the gut by pathogens. Studies into 
gut microbiomes from different countries have identified 
differences in diversity, which reflect the differences in 
diet, geography, early- life exposures and genetics.15 Age, 
diet, antibiotics, probiotics and prebiotics all contribute 
to the shaping of the healthy gut microbiota and this 
continues dynamically throughout life.13 14 16
These differences lead to microbiome dysbiosis, with 
increasing evidence that alterations to the human micro-
biome can affect how well the immune system functions 
and its ability to resist infection17 18; increase the risk of 
developing Parkinson’s disease, multiple sclerosis and 
Alzheimer’s disease,19 the risk of depression, anxiety or 
psychosis20; and indirectly affect the health long term and 
risk of obesity and diabetes.21 There is increasing evidence 
that the microbiome is crucial in a cancer patient’s risk 
of infectious complications.22 Recent studies have shown 
that antibiotic exposure in childhood is associated with 
increased risk for several diseases including obesity, types 
1 and 2 diabetes, inflammatory bowel diseases, Crohn’s 
disease, coeliac disease, autoimmune diseases such as 
allergies, juvenile idiopathic arthritis and asthma.23–26 It 
appears that these effects are most pronounced if the 
antibiotics are consumed within the first 2 years of life and 
the effects may well be cumulative.17 27 28 This is particu-
larly important in young children, when the adult micro-
biome has not been fully established.29 30 Once antibiotic 
treatment has stopped, the microbiome may present a 
certain degree of resilience, being capable of returning 
to a composition similar to the original one, but this is 
poorly understood and can take months or even years.17 31
Differences in perceptions about how risk- free antibi-
otic treatment is may in part account for the enormous 
variation in rates of their use from practitioner to prac-
titioner, between localities and across countries, but also 
within a specific group of practitioners such as GPs. The 
real cost of the most commonly prescribed antibiotics in 
primary care must be clearly understood, including the 
differences between particular antimicrobial agents in 
their effects on the microbiome. This information will 
be specifically useful for antimicrobial stewardship in 
primary care.
AIM
This study aimed to investigate the antibiotic- induced 
changes in gut microbiota for the most commonly 
prescribed antibiotics in primary care in the UK: those 
prescribed for RTIs and UTIs. Our primary outcome was 
defining any antibiotic- induced changes in the composi-
tion of the gut microbiome, measured by (1) abundance 
and/or (2) diversity of the microbes, while our secondary 
outcome measured the time that is needed to restore the 
microbiome to a pre- antibiotic state.
METHODS
A systematic literature review of studies that evaluated the 
association between antibiotics commonly prescribed for 
RTI and UTIs in primary care and their effect on the gut 
microbiome was conducted. Preferred Reporting Items 
for Systematic Reviews and Meta- analyses (PRISMA) 
guidelines and checklist were used as a framework for this 
review (see online supplemental table S1 PRISMA check-
list).32 The study protocol was registered with PROSPERO 
number CRD42017073750 (http://www. crd. york. ac. uk/ 
PROSPERO).
Search strategy
Electronic databases MEDLINE, EMBASE and AMED 
were used to identify relevant articles up to May 2020, 
in English and available as full text. A combination of 
search terms included the following keywords: (antibac-
terial agents OR bacterial infections) AND (microbiota 
OR microbiome). The strategy was designed to identify 
studies conducted in any country, investigating antibiotic- 
induced changes in the human gut microbiota; analysed 
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at either the individual or the population level, published 
in any language (box 1). Reference lists of included 
studies and relevant reviews were hand- searched to iden-
tify additional eligible studies. All selected abstracts and 
citations were exported from the scientific databases 
to the reference management software EndNote X9 
(Thompson Reuters, New York, New York, USA) and 
duplicates excluded.
Study selection and eligibility criteria
A study was eligible for review if it reported quantitative 
changes to the gut microbiota due to treatment with 
antibiotics most commonly prescribed for RTI and UTI 
prescribed in primary care (table 1). RTIs included both 
upper respiratory tract infections (URTIs), including the 
common cold, laryngitis, pharyngitis/tonsillitis, acute 
rhinitis, acute rhinosinusitis and acute otitis media, and 
lower respiratory tract infections (LRTIs), including 
acute bronchitis, bronchiolitis, pneumonia and tracheitis. 
We included uncomplicated and recurrent urinary tract 
infections (UTI and rUTIs). We excluded any animal 
studies or hospital- based studies.
The main exposure of interest in this review was the 
effect commonly prescribed antibiotics have on the gut 
microbiome based on prescriptions advice included in 
the National Institute for Health and Care Excellence 
(NICE) guidelines1 8 33–35 and on current use as described 
in nation reports on antibiotic use.1 34 Of particular 
interest are those antibiotics that are commonly used in 
primary care for the treatment of both upper and lower 
RTIs (amoxicillin, phenoxymethylpenicillin, doxycy-
cline, co- amoxiclav, erythromycin, clarithromycin) 
and UTIs (trimethoprim, nitrofurantoin, amoxicillin, 
cephalexin).
Screening, data extraction and management
Five reviewers (VW, KTE, EvdW, LD and AH) inde-
pendently screened search results and assessed each 
potential study according to the inclusion and exclusion 
criteria. All decisions were recorded on a spreadsheet. 
Full- text papers for all eligible studies were obtained and 
three reviewers (VW, KTE, AH) independently screened 
the selected papers a second time.
The following data were extracted from the included 
studies into an Excel spreadsheet by one reviewer (KTE) 
and a percentage verified for accuracy by another (VW): 
author, journal, year of publication, study design, study 
country, number of participants, number of participants 
of interest to this review, age range, percentage of female 
participants, other inclusion criteria, exclusion criteria, 
recruitment methods, recruitment time period, sample 
type, primary outcome, secondary outcome, antibiotic 
(of interest to this review) used, any other antibiotics 
used, dose of antibiotics (of antibiotic of interest to this 
review), time course (of antibiotic of interest to this 
review), number of timepoints for collecting samples, 
time points for each sample collection, testing method, 
infection or condition, overall conclusion. A tabular 
summary was developed for this review, which included 
study ID, country, design, population, setting, infec-
tion, antibiotic of interest, sample and analysis, primary 
outcome and main results (table 2).
Assessment of methodological quality
Selection bias was assessed with the Critical Appraisal 
Skills Programme (CASP) checklist ( www. casp- uk. net). 
Each component of the studies (ie, the appropriateness 
of the study design for the research question, the risk 
of selection bias, exposure measurement and outcome 
assessment) was graded and an overall grading used to 
produce quality assessment charts based on a traffic light 
system of ‘low’, ‘high’ and ‘unclear’ or ‘not applicable’, 
as recommended by Cochrane.36 Three reviewers (VW, 
KTE, EvdW) independently assessed the risk of bias in the 
studies with two reviewers (KTE, VW) assessing all studies, 
and discrepancies were resolved by consensus between 
the reviewers.
Data synthesis and analysis
Due to the insufficient number of studies available, we 
were unable to undertake any sensitivity analysis to deter-
mine robustness of the findings and the quality of the 
studies.36 The results are discussed descriptively.
Box 1 Search strategy
1. Anti- Bacterial Agents/ae, pd, tu
2. Bacterial Infections/dt, mi
3. Microbiota/
4. (Microbiome or Microbiomes or Gut microbiome or Gut microbiomes 
or Microbiota Gut or microbiota).mp
5. Humans/
6. 1 or 2
7. 3 or 4
8. 6 and 7
9. 5 and 8
Table 1 PICOS criteria for inclusion and exclusion of 
studies
Parameter Inclusion Exclusion
Participants Human adults and children Animals, in 
vitro
Intervention Specific antibiotics of interest 
prescribed in primary care
Other 
antibiotics
Comparator Negative controls or other 
antibiotics
None
Outcomes Changes in gut microbiota, 
total numbers, diversity and 
composition; time taken to 
recover
Antimicrobial 
resistance
Study design All study types None
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Patient and public involvement
This research was done without patient involvement.
RESULTS
Overall
The database searches returned 2475 articles (May 2020). 
Following removal of duplicates and screening of records 
by title or abstract, 2164 were excluded, based on our 
selection criteria (figure 1). One hundred and fifty- nine 
full- text articles were evaluated and a further 128 were 
excluded with reasons detailed in figure 1. Thirty- one 
studies were eligible and included in the present review. 
The included studies are summarised in table 2 and are 
briefly described below.31 37–66 Twelve of the studies were 
published by different authors from the same Swedish 
study group, although one of the studies was carried out 
in Germany.42–44 51 56 59–62 64–66
Publication dates ranged from 1979 to 2017. The 
studies measured the effects on gut microbiota following 
clinical treatment of the patient or experimental expo-
sure of volunteers to different antimicrobial agents.
The 31 publications involved 1068 patients, although 
not all of these received the antibiotics of interest and 
some were comparative control groups. Most studies orig-
inated from European countries, Sweden (11), Finland 
(3), The Netherlands (3), France (2) and one each for, 
Germany, Switzerland, Belgium/Poland and Greece. The 
remaining studies were conducted in the USA (6), Chile 
(1) and Brazil (1).
STUDY CHARACTERISTICS
Sampling
Faecal samples have generally been accepted as repre-
sentative of the intestinal microbiota. Studies conducted 
before 2000 used cultured homogenised faecal samples 
on non- selective and selective media to enumerate 
different colony types. Some isolated pure cultures for 
identification to genus level. The effect of the antibiotic 
was measured by comparing the numbers of bacteria 
present from each genus before treatment with the 
decrease, increase overgrowth or proliferation of other 
bacteria. However, it is known that many types of gut 
bacteria, about 80%, have not been cultured.67 Predomi-
nantly, later studies used more rapid molecular methods.
Analytical techniques
All studies analysed faecal samples, either by culture (17 
studies) or molecular techniques (13 studies), one study 
used both methods. Eighteen of the studies used healthy 
volunteers, four of the studies looked at patients with a 
respiratory infection, three studies patients had a UTI, 
one study reported patients with urinary and respiratory 
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta- Analyses flowchart for study selection.
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infections, one study patients had sinusitis, one study they 
had periodontitis, another study relied on self- reported 
infections and two studies did not specify the health status 
of the subjects.
Risk of bias
The risk of bias among the studies was assessed using the 
CASP checklists for case controls, randomised controlled 
trials (RCTs), other trials and cohort studies (figure 2). 
There was 1 case control appraisal, 15 cohort studies and 
15 trials. All the studies adequately stated their study aims 
and hypothesis and this part of the assessment was rated 
as ‘low’ risk.
Case control
There was one case control study included in our review 
of a patient presenting with onset of diarrhoea not associ-
ated with Clostridium infection, within 24 hours of antibi-
otic administration.49 It was shown that this was associated 
with changes in the diversity of the gut microbiota. In 
terms of bias, the study trends toward overall unclear risk 
as there is lack of controls and the report details just one 
patient in a clinical setting with a symptom of interest 
(figure 2A). However, they did use very robust molecular 
methods to study these temporal changes in the diversity 
of the microbiota.
Cohorts
There were 15 cohort studies included in our review. 
Assessment relating to the validity of the study is covered 
within questions 1–6 (figure 2B). Generally, these studies 
were of low risk. The reliability of the studies determined 
by the size of the effect and how precisely this was esti-
mated are covered with questions 7–9 and are of low or 
unclear risk. There is greater unclear risk when it comes 
to the applicability of the results (questions 10–12), the 
usefulness for clinical decision- making, often the popu-
lation size was too small to extrapolate results to a larger 
population as a whole.
Trials
Fifteen studies included in this review were trials/RCTs 
and overall the risk was more unclear. The validity of the 
studies (Q1-6), randomisation and masking of treatment 
allocation was generally of low risk. The baseline charac-
teristics of the study were of low or unclear risk as most 
studies stated age, gender and health status, a few excep-
tions stated body mass index and ethnicity. Follow- up of 
study participants was of low risk, with most studies taking 
samples up to 4 weeks after antibiotic administration 
(although there are some indications that this needs to 
be longer). Controlling for confounding factors (Q6) was 
unclear in most of the studies. The size of treatment effect 
(Q7) was well reported, but precision (Q8) was unclear, 
mostly due to small population size and lack of statistical 
analysis. The transferability of the results to other popula-
tions (Q9 and 11) was of unclear risk.
Antibiotic effects on the gut
The studies analysed employed different methodologies 
to explore the effect of antibiotics on the gut microbiota. 
They have been consistent in demonstrating that dysbiosis 
develops on antibiotic administration, which is rapid and 
results in losses of diversity and shifts in abundance of gut 
microbes either up or down. After antibiotic treatment, 
the composition generally returns to a similar pretreat-
ment state within several weeks, but not in all cases. Here, 
we describe the results in more detail per antibiotic of 
interest.
Amoxicillin
Ten studies examined the impact of orally administered 
amoxicillin on the normal intestinal microflora and are 
summarised in table 3.37–46 In brief, administration of 
amoxicillin leads to an increase or overgrowth of Entero-
bacteria (six studies). The changes in the anaerobic 
population (includes Lactobacillus, Bifidobacterium and 
Bacteroides) varied enormously between studies: from 
no change, to increases and/or decreases, as well as 
changes in diversity. There were two reports that isolated 
Clostridium and Candida and two where no change in 
numbers were observed. Eight of the studies had some 
longer term follow- up and most of these reported that the 
populations returned to normal within 2–4 weeks. Three 
of the studies reported that significant alterations in the 
microbiome diversity or abundance were still evident 
from 42 days to 6 months after the final antibiotic dose. 
Other longer term effects were a persistence of Candida at 
6 weeks, appearance of other aerobic or resistant Gram- 
negative bacteria (species not specified) at 28 days, and a 
persistent decrease in Lachnospiraceae at 6 months, with 
no similarities in the populations treated.
Christensson et al42 conducted a culture- dependent 
randomised study of 84 subjects with lower respiratory 
tract infections, 38 of whom completed treatment with 
amoxicillin (the remaining received cefaclor and will 
not be discussed further here). They showed that the 
numbers of enterobacteria, anaerobic Gram- positive 
Lactobacilli, Bifidobacteria and Eubacteria, and anaer-
obic Bacteroides increased significantly in the amoxicillin 
group. The number of anaerobic cocci was reduced in 
18 patients and increased in 11 patients. There was no 
change in the abundance of Enterococcus spp, Staphylococcus 
spp or Streptococcus spp. Four patients became colonised 
with Pseudomonas sp and five with C. albicans. Although C. 
albicans was also isolated from two patients pretreatment 
and three patients 6 weeks after treatment C. difficile was 
isolated from two patients during treatment.
The effect of amoxicillin on the intestinal microflora 
of patients with bronchitis was evaluated in a randomised 
study by Floor et al.46 The anaerobic flora remained 
unchanged, both during and after therapy with amoxi-
cillin. The total number of aerobic Gram- negative rods 
increased significantly, and in 37.5% of the patients with 
newly acquired bacteria, the main species identified were 
Klebsiella. Enterococci were cultured in only one patient. 
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Figure 2 Overall risk of bias assessment, for case studies (A), cohort studies (B) and trials (C).
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A third of patients had other aerobic bacteria different 
from baseline on days 21–28. Bacterial and fungal abun-
dance returned to baseline levels 21 days after treatment.
Mangin et al41 studied 18- month old children with 
acute bronchitis. Both total bacteria and numbers of 
Bifidobacteria were similar during the course of antibi-
otic treatment. However, changes in Bifidobacterium at 
the species level showed decreased diversity. Amoxicillin 
treatment induced a complete disappearance of Bifido-
bacterium adolescentis species, a significant decrease in the 
occurrence rate of Bifidobacterium bifidum, but did not 
affect Bifidobacterium longum and Bifidobacterium pseudoca-
tenulatum/Bifidobacterium catenulatum. They did not study 
longer term effects.
Monreal et al38 used culture- based methods to examine 
the populations of faecal bacteria in 22 patients with RTIs 
treated with amoxicillin. Bacteroides spp, Bifidobacterium 
spp and Lactobacillus spp were decreased with antibiotic 
treatment. However, this was only transient, and 30 days 
after the end of treatment, the levels of Bifidobacterium 
and Lactobacillus had recovered to their normal values. 
Bacteroides were slower to recover.
Ladirat et al45 studied a small number of healthy volun-
teers with amoxicillin and a prebiotic specifically looking 
at total bacteria and Bifidobacterium. Numbers of Bifidobac-
terium decreased over time due to amoxicillin treatment, 
especially in the group with no prebiotic. Amoxicillin 
affected the abundance and diversity of Bifidiobacterium 
spp and there was an overgrowth of Enterobacteriaceae. 
The observations were highly individual dependent. In 
the follow- up period (3 weeks after the discontinuation 
of amoxicillin treatment), the levels of bifidobacterial in 
faeces returned to the initial levels.
Amoxicillin was administered randomly to a small 
number of healthy volunteers and the impact on intestinal 
microflora (and oropharyngeal) was studied by Brismar et 
al.43 In the aerobic intestinal flora, a minor decrease in the 
numbers of streptococci and staphylococci was observed. 
Overgrowth of Klebsiella species was seen in six subjects 
and of Enterobacter species in two subjects. No overgrowth 
of enterococci or yeasts occurred. In the anaerobic micro-
flora, only the number of eubacteria was reduced. There 
was no colonisation by C. difficile. Two weeks after admin-
istration of amoxicillin, the microbiota had returned to 
baseline levels.
Another study on the effect of amoxicillin on intestinal 
microflora of healthy volunteers showed only small alter-
ations in the aerobic faecal microflora.44 All major anaer-
obic bacterial groups were unaffected by amoxicillin and 
there was no colonisation by C. difficile. There was an over-
growth of Klebsiella spp in six subjects and Enterobacter in 
two subjects. Intestinal microflora returned to normal 2 
weeks after treatment had been discontinued.
Six healthy volunteers received oral amoxicillin for 5 
days and their faecal microbiota examined by 16S rRNA 
gene amplification and gradient gel electrophoresis 
until 60 days.37 Dominant species diversity profiles were 
compared on the basis of similarity with percentages on 
first sampling ranging from 93% to 99%. During the 
5- day course of amoxicillin treatment, these percentages 
decreased to an average of 73%, but there was huge varia-
tion between individuals. By day 60, five of the six subject 
gel profiles had returned to their near initial composi-
tion. Gel banding patterns were examined in more detail 
for three individuals and were shown to correspond to 
Clostridium nexile, Ruminococcus torques and β- Proteobacteria.
Abeles et al40 studied cohabiting individuals over 6 
months where one was given an antibiotic and the other 
a placebo. The microbiota of subjects taking amoxicillin 
grew more dissimilar over time, although not statisti-
cally significant, as similar trends were also seen in those 
subjects taking placebo. Taxonomic compositions of the 
gut differed after amoxicillin therapy. Lachnospiraceae 
were significantly diminished and remained diminished 
at 6 months. Veillonellaceae, Bacteroidales and Porphy-
romonadaceae were significantly decreased in response 
to amoxicillin, while Fusobacteriaceae were increased. 
Bifidobacteriales and Erysipelotrichaceae were initially 
decreased and subsequently increased in comparison to 
their housemates taking placebo.
Pallav et al39 studied the effect of amoxicillin treatment 
with and without a prebiotic. Eight subjects that received 
just the antibiotic had substantial microbiome changes, 
most notably an increase in Escherichia/Shigella. There was 
no change in abundance in the control group. Antibiotic- 
associated changes persisted to the end of the study, 42 
days after antibiotic therapy ended.
Amoxicillin with clavulanic acid
Seven studies have looked at the impact of amoxicillin 
in combination with clavulanic acid on the gut micro-
biota.31 47–52 These are summarised in table 4. Briefly, the 
combination of amoxicillin with clavulanic acid caused 
mild to moderate changes in microbiome composition, 
mainly increases in Enterobacteria with varying effects on 
anaerobic bacteria Bifidobacterium sp, Lactobacillus sp and 
Bacteroides sp and a general decrease in diversity. One study 
reported that bacterial abundance was not normalised 2 
months after antibiotic treatment was stopped, and four 
reported levels similar to baseline within 35 days.
Administration of amoxicillin/clavulanic acid to 
healthy people caused increased numbers of enterococci 
and Escherichia coli strains in the aerobic microflora, while 
Bifidobacteria, Lactobacilli and Clostridia decreased 
significantly.51 Numbers of anaerobic cocci and Bacteroides 
were not markedly altered. C. difficile strains were recov-
ered from three of the volunteers. The microflora was 
normalised in all volunteers after 35 days.
Young and Schmidt49 investigated the short- term impact 
of amoxicillin/clavulanic acid prescribed for a male 
patient with acute sinusitis, who developed antibiotic- 
associated diarrhoea. It was shown that the major bacte-
rial groups were partially restored 14 days after antibiotic 
treatment, except for Bifidobacterium. During antibiotic 
administration, no sequences corresponding to butyrate- 
producing Clostridium cluster XIVa were detected, but 
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2 weeks after cessation of antibiotics, there was a reap-
pearance of this cluster. In this case study, the decrease 
in this cluster may be linked to the antibiotic- associated 
diarrhoea.
One arm of a study by Engelbrektson et al50 observed 
the effects of probiotic treatment concurrent with antibi-
otic therapy on faecal communities. They analysed their 
data by measuring individual divergences from baseline 
levels after treatment to address the problem of subject- 
to- subject variability. Subjects fell into two categories: 
those with a stable baseline microbiota and those where 
it varied significantly. Culture data showed increasing 
numbers of Bacteroides and Enterobacteriaceae, but no 
trend for Clostridium, Bifidobacterium and Lactobacillus. The 
antibiotic group (without probiotic) had a significant 
change in numbers of bacteria from baseline at day 21.
Forssten et al48 also studied antibiotic administration in 
combination with probiotic. Consumption of the probi-
otic combination mainly led to an increase in the faecal 
levels of the species included in the preparation. The 
antibiotic had only minor effects on Lactobacillus, Bifido-
bacterium, Bacteroides, Enterobacteriaceae and Clostridium.
Korpela et al31 looked at the macrolides amoxicillin 
with and without clavulanic acid and penicillin V. Macro-
lide use reduced the abundance of Actinobacteria and 
increased Bacteroidetes and Proteobacteria. Penicillin 
groups did not have distinctly different phyla composi-
tion. Firmicutes was reduced. The effect of macrolide use 
was long lasting and was associated with increased risk of 
asthma and antibiotic- associated weight gain.
Twelve healthy subjects received amoxicillin/clavulanate 
for 7 days and their stool specimens were analysed using 
16s rRNA gene pyrosequencing.52 Antibiotic- associated 
changes included reduced prevalence of the genus Rose-
buria and increases in Escherichia, Parabacteroides and Entero-
bacter. Microbiota alterations reverted toward baseline, 
but were not completely restored 2 weeks after treatment.
Real- time PCR with temporal temperature gradient gel 
electrophoresis (TTGE) showed that at the end of a 5- day 
course of amoxicillin- clavulanic acid, total bacterial and 
Bifidobacteria concentrations were significantly reduced 
in 18 healthy volunteers.47 At the same time, the mean 
similarity percentage profiles were significantly reduced 
and the number of distinct Bifidobacterium species per 
sample significantly decreased. Two months after anti-
biotic exposure, the mean similarity percentage had not 
normalised.
Nitrofurantoin
Three studies investigated the effect of nitrofurantoin 
macrocrystals on faecal microbiota compositions.53–55 
Two studies used 16S rRNA gene sequencing and one 
study bacterial culture and these are summarised in 
table 2. Nitrofurantoin inhibits bacterial DNA, RNA and 
cell wall protein synthesis. It is used prophylactically as 
a urinary anti- infective agent against most gram- positive 
and gram- negative organisms and for long- term suppres-
sion of infections. On oral administration, most of the 
nitrofurantoin is rapidly absorbed in the small intestine 
and eliminated primarily by kidney glomerular filtration 
into urine, where it reaches higher and more effective 
therapeutic concentrations. Only a small amount reaches 
the colon, which may account for the minor impact on 
intestinal microflora.
One of the studies investigated a small population of 
women (n=7) with recurrent UTI and it showed that 
nitrofurantoin did not alter either the Enterobacteria, 
Enterococci or yeasts of the colonic flora during treat-
ment.55 No resistant strains of Gram- negative aerobic 
bacteria were detected.
Stewardson et al53 treated patients with UTI (n=10) with 
nitrofurantoin macrocrystals and showed that it was not 
associated with a statistically significant global impact on 
the gut microbiota (weak effect). Nitrofurantoin treat-
ment was associated with an increase in the proportion of 
the genus Faecalibacterium and a decrease in the proportion 
Clostridium (Clostridiaceae) at the end of the antibiotic 
treatment. Another small study (n=8) treated uncompli-
cated UTIs and did not show any significant impact of 
nitrofurantoin treatment on the faecal microbiota other 
than a temporary increase in the Actinobacteria phylum, 
more specifically in the beneficial Bifidobacterium genus.54 
Bacterial abundance had returned to pre- antibiotic levels 
31 to 43 days after stopping antibiotic treatment, while 
the other study did not do follow- up testing.53 54
Doxycycline
Four studies reported on the effect of doxycycline on 
faecal microbiota, one at suboptimal dosage (20 mg for 
9 months) in patients with periodontitis57 and two at 
usual dose 100–150 mg for 7–10 days, although one also 
with a probiotic,56 58 and another at low dose (40 mg for 
16 weeks),59 as described in table 2. Doxycycline treat-
ment did not significantly affect counts of total anaer-
obic bacteria, candida, total enterics, Staphylococcus or 
doxycycline- resistant bacteria recovered at any of the 
sample periods and did not result in the development 
of multi- antibiotic resistance.57 Matto et al58 specifically 
evaluated the influence of doxycycline therapy on the 
composition and antibiotic susceptibility of intestinal 
Bifidobacteria in nine subjects while they were also taking 
a probiotic and compared these to adults consuming 
only probiotics. A marked decrease in diversity of Bifido-
bacterium populations was observed during doxycycline 
therapy. Tetracycline- resistant Bifidobacterium isolates were 
more commonly detected in the antibiotic group than in 
the control group, thus increasing the pool of resistant 
commensal bacteria in the intestine.
In another study on 10 healthy volunteers, doxycy-
cline decreased the abundance of Enterobacteriaceae, 
Enterococcus spp, E. coli and Streptococcus spp.56 With the 
exception of Fusobacterium spp, which was eliminated, 
the number of anaerobic bacteria in faeces was not 
influenced by doxycycline.56 After doxycycline admin-
istration, bacterial abundance was reported to have 
returned to pre- antibiotic levels 9 days after stopping 
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treatment.56 The fourth study also looked at a low dose 
over a period of 16 weeks.59 There were 2 log decreases 
in the numbers of enterococci and E. coli. Other aerobic 
microorganisms including enterobacteria, Candida spp, 
were not affected. There were no significant changes 
in the numbers of anaerobic lactobacilli, bifidobacteria, 
clostridia and Bacteroides during doxycycline administra-
tion.59 No C. difficile strains were isolated. The aerobic 
and anaerobic microflora was normal at 28 days after 
stopping treatment.59 In summary, doxycycline inter-
feres with a microorganism’s ability to manufacture 
proteins. At suboptimal dosage, it has little effect on the 
gut microbiota with the exception of enterococci and E. 
coli. At normal dosage it markedly affects the diversity of 
Bifidobacteria populations in one study and eliminated 
Fusobacterium sp in another. The effect on populations 
of other gut bacteria seems transient and normalisation 
was reported by 28 days. Longer term effects are not 
known.
Clarithromycin
There were four articles on influence of clarithromycin 
included. Three were from the same research institute, 
and these examined the intestinal microflora of healthy 
volunteers before, during and after administration of 
clarithromycin. The study design was similar in all three 
studies and involved small numbers, 10 (a mix of male 
and female subjects) in two studies60 62 and 12 men only61 
as described in table 2. Dosing and faecal sampling 
strategy and analysis were also similar, 250 mg twice daily 
for 7days,59 500 mg twice daily for 7 days,60 and 250 mg 
twice daily for 10 days,62 sampling three times during and 
three to four times after administration up to 35 days. 
The male- only subjects were administered another antibi-
otic with a 6- week washout period; it is not clear whether 
this was before or after clarithromycin administration.
The main impact in the earlier study was a reduction in 
the numbers of Enterobacteria and Streptococci. Lacto-
bacilli, Bifidobacteria and Bacteroides were suppressed in 
the anaerobic microflora.60
Clarithromycin caused a significant reduction of E. 
coli during 7 days of treatment but levels returned to 
normal 28 days after the end of the course.61 Six subjects 
were colonised by resistant aerobic Gram- negative rods, 
Citrobacter, Klebsiella, Proteus and Pseudomonas. The total 
numbers of anaerobic bacteria decreased. Bifidobacteria 
and Bacteroides were significantly reduced, and Lactoba-
cilli and Clostridia were suppressed but this was not signif-
icant. There was no overgrowth of C. difficile or yeasts. The 
microflora returned to normal in all subjects after 35 days.
In the final study, the numbers of E. coli were signifi-
cantly reduced, and in six individuals, overgrowth of Kleb-
siella, Citrobacter and Enterobacter spp occurred.62 The total 
number of anaerobic intestinal bacteria was not affected, 
but the numbers of Lactobacilli and Bifidobacteria were 
significantly reduced which persisted for the duration of 
the study. There was no significant overgrowth of Candida 
spp and no subjects were colonised by C. difficile.
A fourth study from a different group on six healthy 
volunteers showed no change in the abundance of 
Candida spp, Enterococcus spp or anaerobic bacteria. There 
was no new colonisation by C. difficile. Numbers of Entero-
bacteriaceae decreased slightly. Levels were reported to 
have returned to baseline by day 21 after the course of 
clarithromycin.
To summarise, all four studies reported reduction in 
Enterobacteria and three reported suppression of anaer-
obic bacteria after administration of clarithromycin. This 
reduction was transient for most species, except Lacto-
bacilli and Bifidobacteria. Only one studied reported 
isolation of C. albicans.60 None reported new colonisation 
or overgrowth of C. difficile. All reported normalisation 
to baseline levels within 28 days of finishing antibiotic 
treatment.
Phenoxymethylpenicillin
Phenoxymethylpenicillin did not have much effect on gut 
microbiome, as shown by two studies that investigated the 
effect on the oropharyngeal and intestinal microflora of 
healthy volunteers (table 2).64 65 A very early study reported 
no effect of phenoxymethylpenicillin on abundance of 
various species comprising the aerobic and anaerobic 
flora of faecal samples.64 A later study showed no signifi-
cant alterations in the total aerobic and anaerobic of the 
intestinal microflora were observed, although three volun-
teers became newly colonised with Klebsiella sp and one 
harboured high numbers of a non- fermentative Gram- 
negative rod. The numbers of viridans streptococci, entero-
cocci and Bacillus were unaffected by the administration 
of phenoxymethylpenicillin, while minor alterations were 
noticed in the numbers of E. coli. The median values of Clos-
tridium species increased during administration, while the 
numbers of Bacteroides species were unaffected during the 
study period. The microflora became normalised 2 weeks 
after withdrawal of the drugs.
Erythromycin
In an early study,66 it was shown that the administration of 
500 mg of erythromycin twice daily for 7 days to 10 volun-
teers resulted in decreased abundance of both aerobic 
and anaerobic faecal flora. In addition, potentially patho-
genic erythromycin- resistant enterobacteria, clostridia or 
yeasts colonised all subjects.66 Brismar and colleagues60 
administered erythromycin orally for 7 days to 10 volun-
teers and evaluated its effect on the colonic bacteria. 
They found decreases in the numbers of streptococci, 
enterococci and enterobacteria during administration, 
increases in staphylococci and alteration of the anaerobic 
bacteria.
DISCUSSION
Main findings
This systematic review examined the use of the most 
commonly prescribed antibiotics in primary care to 
treat RTI and UTI and their impact on gut microbiota. 
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First, the studies showed that antibiotics have an impact 
on the abundances of the bacteria in the gut commu-
nity, causing rapid and diminished levels of bacte-
rial diversity and taxonomic richness, increases and 
decreases in the relative abundances of certain taxa, 
leading to dysbiosis, as well as antibiotic and individual 
host- specific effects.
Second, once treatment has stopped, there was some, 
but poor, evidence that the gut bacteria show resilience 
and are capable of some degree of recovery, in most indi-
viduals, to their initial state. However, the microbiota is 
often not totally recovered, suggesting some antibiotics 
have a persistent effect on certain species. These observa-
tions underline the importance of restrictive and proper 
use of antibiotics in order to prevent long- term ecological 
disturbances of the indigenous microbiota.
Comparative observations
Other reviews have also reported and summarised how 
antibiotics change the abundance and diversity of the 
intestinal microbiota.68–70 Here, we focus on those antibi-
otics routinely prescribed by general practitioners (GPs) 
in primary care. Often GPs inappropriately prescribe 
antibiotics for infections caused by viruses, or prescribe 
a broad- spectrum antibiotic, when an antibiotic for a 
specific bacteria should be used. They may also prescribe 
the incorrect dose or for the wrong length of time. Health 
professionals are concerned that antibiotics are used too 
often and incorrectly, which contributes to antimicrobial 
resistance and with the additional disruption to the micro-
biome also can have other negative (long term) health 
effects, such as metabolic and immune disorders.71 72 
These additional effects will further impact on the patient 
and potentially on the primary care burden. Inappropriate 
prescribing is due to many factors including patients who 
insist on antibiotics, GPs who do not have enough time 
to explain why antibiotics are not necessary those who do 
not know how to recognise a serious bacterial infection or 
those who are overly cautious.
Quantifying antibiotic therapy effect on gut flora is 
challenging. Although the literature describes ‘normal’, 
it really means those commensal species which are 
consistently and predominantly found in the healthy 
human gut. Studies quantifying changes in flora would 
be easier to interpret if a baseline populations were 
established in each case. We found a lack of large- scale 
trials (including RCTs) and observational studies and 
heterogeneity regarding methodology and outcomes. 
The heterogeneity is apparent by the inconsistency in 
the dosage, duration of treatment and follow- up, selec-
tion and spectrum of antibiotics used, all contributing to 
varying faecal concentrations. The health status and age 
of the participant also have an effect, most studies did 
not clearly define baseline characteristics, which causes 
problems with comparing outcomes. The majority of 
studies did not report adverse events or any other factors 
which might affect the efficacy of the antibiotic which 
in turn might influence the outcome on the micro-
biome. The studies included used different methods, 
for example, random allocation of antibiotics to healthy 
volunteers, or non- randomised treatment where all 
healthy subjects in the study received antibiotics, also 
some studies participants were masked to which treat-
ment they received and others were not. There were 
differences between studies in the way outcomes are 
defined and measured, for example, culturing versus 
molecular techniques. These differing analytical tech-
niques may lead to differences in the observed interven-
tion effects. A number of the included studies originate 
from one research group which could add additional 
bias to the outcomes. The different classes of antibiotics 
also have different effects on the microbiome, making it 
difficult to compare across studies.
The composition of the gut microbiota among humans 
varies considerably from subject to subject. Grouping 
of data from several individuals can result in loss of 
statistical significance. The studies do not consider any 
confounding factors such as diet, age of subjects, child-
hood exposure to antibiotics, geographical location, 
stress or taking probiotic supplements, all of which can 
complicate the specific antibiotic treatment effects on the 
gut microbiome profile. These factors can change over a 
lifetime.
Strengths and limitations
The primary strength of this study is our focus on the 
most commonly prescribed antibiotics in primary care and 
their effect on gut microbiota. Information on how these 
commonly prescribed antibiotics affect our gut microbiome 
could influence GP decision- making when prescribing 
antibiotics. Also, the adverse impact of antibiotics on the 
gut microbiome is of great importance because when 
disrupted, it can be associated with a variety of diseases, 
including susceptibility to infections, autoimmune diseases 
(such as inflammatory bowel disease), diabetes, depression 
and obesity. The main limitations of this review are that 
the majority of the studies included were small, not prop-
erly randomised nor they were large observational studies. 
The considerable heterogeneity is prone to biases and 
confounding factors.
Inherent in many studies that address the impact of 
antibiotics on the intestinal microbiota are the limita-
tions of techniques available for analysis. Many have been 
performed using laborious culture- based methodology 
which do not lend themselves to analysis of large numbers 
of samples. The older studies included in our analysis all 
used culture- based techniques to examine gut microbiota 
composition, which increases the risk of detection bias. 
The disadvantage of using culturing is that despite the 
use of specific selective media and anaerobic incubation 
conditions, there remains a substantial part of the micro-
biota, approximately 80 %,67 that has not yet been cultured. 
Culture media choice and sample handling can also skew 
the data.
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The limitations of culture- based techniques can be 
largely overcome by using molecular approaches.73 
These methods are based on 16S rRNA gene amplifica-
tion and give us a broader less biassed view of gut bacte-
rial composition. The amplified genes are characterised 
by methods, such as terminal- restriction fragment length 
polymorphism, denaturing or temperature gradient 
gel electrophoresis, deep shotgun metagenome and 
full- length sequencing, some of which are used in the 
more recent papers in our review. These bioinformatic 
techniques also have limitations in that they are often 
more difficult to understand and interpret. The use of 
different techniques makes it more difficult to compare 
results, and generalisation of conclusions is a result of 
this diversity in determination and quantification.
CONCLUSIONS
The widespread and often overuse of antibiotics has led to 
the establishment of antibiotic- resistant bacteria and the 
transfer of resistance genes, which has become a global 
challenge for infection control and the untreatable nature 
of bacterial infections. Almost 80% of the antibiotics 
prescribed within the National Health Service are within 
primary care.1 The effects of excessive antibiotic exposure 
can also be seen in the symbiotic microbiotas of the human 
body.74 As a result, the microbiota imbalances caused by 
antibiotics can negatively affect health by increasing suscep-
tibility to infections, compromising immune homeostasis 
(indicative in increased allergies), asthma, seen by obesity, 
metabolic syndrome and diabetes.75
Antibiotics have an impact on the gut microbiota, 
causing rapid and diminished levels of bacterial diver-
sity and increases and decreases in the relative abun-
dances, leading to dysbiosis. Once treatment has 
stopped, there was some evidence that the gut bacteria 
are capable of some degree of recovery, in most individ-
uals, to their baseline state. The studies do not consider 
that recovery of the microbiome after antibiotic therapy 
in the elderly may be affected by age- associated physi-
ological alterations and other drug–drug interactions.
This systematic review highlights the lack of research 
and understanding of the effects of commonly prescribed 
antibiotics on the gut microbiome and shows it is an area 
that requires studies on larger populations with extended 
sampling to understand the long- term impacts. Embed-
ding of this knowledge in antimicrobial stewardship 
programmes in primary care will be essential.
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